Glioblastoma Multiforme Treatment Market – By Treatment, By Drug Class, By Dosage Form, By Gender, By End Use - Global Forecast, 2024 – 2032

Glioblastoma Multiforme Treatment Market Size

The global glioblastoma multiforme treatment market size was valued at USD 2.9 billion in 2023 growing at a CAGR of 8.6% from 2024 and 2032. The growth of market was driven by the global increase in the prevalence of glioblastoma multiforme disease that necessitates the demand for novel drug therapies to provide effective treatment.
 

For instance, as per the National Brain Tumor Society report, GBM accounts for 50.1 percent of all primary malignant brain tumors. It is estimated that more than 10,000 individuals in the U.S. succumb to glioblastoma every year. This indicates an increasing investment from key pharmaceutical players to support research and development activities for the development of innovative treatment options. Lisata Therapeutics, Inc. announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”). Thus, the increasing investigator-initiated study, leads to development of more sophisticated treatment for GBM.
 

Furthermore, the growing support from the regulatory authorities such as U.S. FDA and European Medicine Agency for the approval of new drugs is growing the interest of key pharmaceutical companies to invest in GBM research. For example, in December 2021, Sapience Therapeutics, received fast track designation to its lead program investigating ST101 for the treatment of recurrent glioblastoma (GBM) from U.S. Food and Drug Administration (FDA). ST101 could improve outcomes for patients suffering from GBM. In addition, growing demand for personalized medicine raises the demand for next-generation sequencing and biomarker based therapies.
 

Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. It invades the nearby brain tissue but does not spread to distant organs. GBMs can arise in the brain de novo or evolve from lower-grade astrocytoma. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. GBM is a devastating brain cancer that can result in death in six months or less, if left untreated.
 

Glioblastoma Multiforme Treatment Market Trends

Patients suffering from GBM have been given hope through the development of treatment options which in effect have increased the survival rate of many patients, benefiting the market overall. For example, in October 2023, the U.S. FDA granted fast-track designation to DOC1021, a new molecule for the treatment of glioblastoma multiforme. The way the vaccine works and how it is given suggests that the immune system can be used to fight glioblastoma. The aim for development of better treatment options is elevated and in turn, the market is on a steep rise.
 

• In addition, the ever-increasing patient population will need to be catered to with a higher level of healthcare, including ancillary services. Moreover, pharmaceutical companies have increased focus to create novel products and compete with other companies, thus improving the standards of care and treatments available for patients suffering from glioblastoma multiforme.
   
• Further, the growing spending on research and development intended for glioblastoma treatment with funds from the National Cancer Institute, The Brain Tumor Charity and National Brain Tumor Society is triggering market expansion. For instance, the Glioblastoma Research Organization (GBMRO) has the highest donation toward funding Project DeLaRosa with Children’s National Hospital by USD 80,000.
   
• Besides, the rising use of AI for the diagnosis enables more accurate treatment selection and improves the service quality which also help in increasing the revenue.
   

Glioblastoma Multiforme Treatment Market Analysis

Based on the treatment type, the global market is classified into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy. The radiation therapy segment dominated the market in 2023 and was valued at USD 826.2 million in 2023 growing from USD 708.8 million in 2021.
 

• The recent advancements in radiation therapy technologies such as the introduction of intensity modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS) are used to provide high-dose radiation with more precision and reduce the damage to surrounding healthy issues, thereby contributing to market growth.
   
• For instance, as per the data presented at the American Association for Cancer Research, AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in recurrent GBM patients.
   
• Radiation therapy is commonly used along with combination therapy. Drugs such as temozolomide used as a standard-of-care treatment when combined with radiation therapy.
   
• Moreover, the heightened awareness of brain tumor and improved diagnostic technology lead to earlier detection of disease. Thus, the early diagnosis of disease with ongoing research and clinical trials for providing better treatment planning and outcomes contribute to market growth.
   

Based on the drug class, the global glioblastoma multiforme treatment market is classified into temozolomide, bevacizumab, lomustine, and carmustine wafers. The temozolomide segment dominated with market share of 40.2% in 2023 and is anticipated to witness growth at a CAGR of 8.9% during the analysis period.
 

• Temozolomide drug is considered as a first line therapy for glioblastoma multiforme used with radiotherapy and surgical resection. Also, temozolomide can cross the blood brain barrier that increases the efficacy of drugs when compared to other chemotherapies.
   
• The increasing number of combination therapy of temozolomide with emerging therapies improve the efficacy of the drug, which boost the market growth. For example, as per the study conducted by the Society of Neuro-oncology reported that, both radiation and temozolomide is more effective than radiation therapy alone in patients with gliomas. As per the studies conducted it has been observed that temozolomide improves long-term survival for patients with GBM.
   
• Moreover, the key pharmaceutical players are continuously involved in research and development activities to improve the efficacy of drug by introducing innovative drug delivery strategies. The introduction of nanoparticle-based TMZ delivery and the ongoing clinical trials on liposome encapsulation technology for enhanced TMZ bioavailability is increasing investment in GBM research.
   
• Therefore, the growing awareness among healthcare professionals and patients pertaining to the benefits of temozolomide for glioblastoma, coupled with growing adoption of chemotherapy is fueling the market growth.
   

Based on dosage form, the glioblastoma multiforme treatment market is classified into oral and parenteral. The oral segment was valued at USD 1.8 billion in 2023 and is expected to reach USD 3.8 billion by 2032.
 

• The increasing shift towards traditional intravenous therapy to oral dosage form owing to increasing patient preference for non-invasive home-based treatment and advancement in oral drug delivery system contributes the market growth.
   
• The increase in the number of oral drugs getting regulatory approval leads to a greater number of products available for GBM treatment. In August 2024, Servier announced that the U.S. Food and Drug Administration (FDA) has approved VORANIGO, indicated for the treatment of adult and pediatric patients 12 years and older with glioma. VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.
   
• Therefore, the introduction of newer oral therapies that cross the blood-brain barrier more effectively and target tumor cells specifically are increasingly used for GBM treatment, potentially improving survival rates in patients.
   

Based on gender, the glioblastoma multiforme treatment market is classified into male and female. The male segment dominated the market with 64.5% share in 2023 and is expected to exhibit 8.8% CAGR between 2024 – 2032.
 

• The high prevalence of GBM in male population, increases the product demand to provide better treatment options tailored to male population. For instance, as per an article published in Springer journal, it has been reported that GBM is more common in men, with the incidence rate of 1.57%, higher in males than in females.
   
• Moreover, the leading pharmaceutical and biotech companies are heavily investing in targeted therapies to offer better treatment options to male patient, contributing the market growth.
   
• Furthermore, the increasing number of awareness campaigns by organization such as the Brain Tumor Foundation and the National Brain Tumor Society leads to early detection of disease, thereby fostering the demand for effective treatment access, thereby augmenting the market growth.       
   

Based on end use, the glioblastoma multiforme treatment market is classified into hospitals, cancer treatment centers, ambulatory surgical centers, and other end users. The hospitals segment is expected to reach USD 2.5 billion by end of 2032.
 

• The hospital settings are at the forefront of adopting the latest technologies for the quick and precise diagnosis of disease and offer personalized treatment.
   
• They are staffed with better treatment capabilities, which include specialized neuro-oncology units for the management of brain tumors. This specialized care makes the hospitals preferred and therefore enhances the growth of the market.
   
• In addition, many hospitals worked together with pharmaceutical companies like Bristol Myers Squibb, Novartis, and Eli Lilly for research purposes and clinical trials. The Global Coalition for Adaptive Research in collaboration with the Cure Brain Cancer Foundation launched GBM AGILE in Australia in November 2023.
   
• GBM AGILE is the first patient-adaptive platform trial designed to simultaneously assess multiple potential therapies for adults newly diagnosed with and those who have recurrent glioblastoma (GBM). The trial is termed patient-centered, as its creation stemmed directly from patients' needs.
   
• Furthermore, more reimbursement schemes are being availed by many hospitals besides receiving support from insurance companies enabling hospitals to reach a wider population and providing comprehensive cancer care including major surgeries, chemotherapy, and other advanced therapies for GBM which in turn, propels the growth of the market.
   

North America glioblastoma multiforme treatment market secured a substantial market share of 39.5% in 2023 and is expected to reach USD 2.4 billion through the forecast period.
 

• The presence of key pharmaceutical players and academic institutes in the region that majorly focus on cancer research and invest in biological and immunotherapy treatment boosts market growth.
   
• The increasing focus on novel drug therapies and treatment approaches in the country, with easy availability of targeted therapies, gene therapy and immunotherapies for GBM treatment drives the growth of the market.
   
• Also, the ongoing clinical trials such as GBM-impact and GBM-agile create new growth opportunities in the market. For example, in November 2024, Novocure announced the U.S. Food and Drug Administration (FDA) approval of new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme (GBM).
   
• Moreover, the increasing investment from the venture capital and biotech firms for the companies working on GBM treatment drives the market growth. For instance, the NIH invested over $1.3B in glioblastoma research with the focus of developing novel GBM therapies.
   

Germany to experience the highest growth rate in the Europe glioblastoma multiforme treatment market in 2023.
 

• The presence of robust healthcare infrastructure in the Germany offers cutting-edged diagnostic technology that support the diagnosis and treatment of GBM.
   
• The ongoing research on GBM and other cancers is being funded by the German government and private institutions. For instance, research on neurology and oncology, including GBM treatment, is funded by Germany's Federal Ministry of Education and Research (BMBF).
   
• Furthermore, innovative GBM treatments are also being developed in Germany owing to increasing collaborations between pharmaceutical companies, academic institutions, and research centers. Players like Boehringer Ingelheim and Bayer are at the forefront of research on brain tumors and cancer, thereby supporting market growth.
   

The Asia Pacific glioblastoma multiforme treatment market is expected to grow with a significant CAGR of 9% during the forecast period.
 

• The increasing prevalence of glioblastoma multiforme along with investment in the region is a significant driver. The Government of India allocated over USD 300 million for oncology R&D, promoting clinical trials and access to global standard treatment.
   

• Also, the introduction of generic version of the chemotherapy drug such as temozolomide, made treatment easy affordable to every people, thereby stimulating the regional market growth.
   

• Moreover, the government initiatives in brain tumor research and expansion of healthcare infrastructure across Asia Pacific countries, further propelling market growth. For instance, the Australian Brain Tumor Mission allocated over USD 136.7 million in December 2022 for brain tumor research with the goal of doubling survival rates and enhancing patient quality of life.
   
• Similarly, the government organizations such as Cancer Patients Aids Association and Tata Trust are raising awareness about early symptoms of brain tumors, leading to earlier detection and improved survival rates.
   

Brazil to experience the highest growth rate in the Latin America glioblastoma multiforme treatment market in 2023.
 

• Brazil's diversified patient population and expanding clinical research infrastructure have made it a desirable location for international pharmaceutical companies to perform clinical studies for the treatment of glioblastoma. For instance, in 2023, MSD (Merck & Co.) initiated a clinical trial in Brazil for its prominent drug Keytruda which is a checkpoint inhibitor used in GBM treatment. The treatments are accessible through the Unified Health System (SUS), which offers free or heavily discounted cancer therapy.
   
• Furthermore, the development of radiotherapy services in large hospitals is one result of the Brazilian Ministry of Health's increased financing for public cancer centers.
   
• Additionally, greater use of robotic surgery to remove tumors precisely and improved availability of precision medicine for the treatment of brain cancer drives the country level market growth.
   

Glioblastoma Multiforme Treatment Market Share

Top 5 players such as Teva Pharmaceuticals, Amgen, Merck, Roche, and Pfizer accounts for approximately 55% of the market share. These players focus on various strategies such as acquisition, business expansion, research and development activities and novel product launches to consolidate their market presence. For instance, as per the January 2025 data Glasdegib is under clinical development by Pfizer and currently in Phase II for glioblastoma multiforme (GBM).
 

As per the reports phase II drugs for glioblastoma multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into phase III. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for glioblastoma multiforme treatment.
 

Glioblastoma Multiforme Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below:

• Amgen
• Amneal Pharmaceuticals
• Curtana Pharmaceuticals
• Denovo Biopharma
• Eisai Co (Gliadel)
• F. Hoffmann La Roche (Genetech USA)
• Karyopharm Therapeutics
• Merck & Co
• Novocure GmbH
• Pfizer
• Sumitomo Dainippon Pharma 
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
   

Many leading players such as Sun Pharmaceuticals, focuses on mergers and acquisitions to gain competitive edge in the market. For instance, in October 2024, Sun Pharma has entered into a global licensing agreement for commercializing Swiss Italian biotech Philogen’s specialty anti-cancer immunotherapy Fibromun (L19TNF).
 

Fibromun is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma (malignant forms of brain tumors). Companies are also focusing on expansion of their existing business by establishing more products for GBM.
 

Glioblastoma Multiforme Treatment Industry News:

• In October 2024, Alpha Tau Medical Ltd announced that Alpha DaRT has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme.
   
• In November 2023, Rznomics Inc., a South Korea based biopharmaceutical company announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for RZ-001, for the treatment of patients with glioblastoma (GBM). This strategy is expected to enhance the company’s outreach to untapped economies.
   
• In December 2022, Moleculin Biotech, Inc., announced that the U.S. Food and Drug Administration has granted fast track designation of WP1122 for the treatment of glioblastoma multiforme.
   
• In January 2022, ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, and Helmholtz Munich (Helmholtz Zentrum München), announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma.
   

The glioblastoma multiforme treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Surgery
• Radiation therapy
• Chemotherapy
• Targeted therapy
• Tumor treating field therapy
• Immunotherapy

Market, By Drug Class

• Temozolomide
• Bevacizumab
• Lomustine
• Carmustine wafers

Market, By Dosage Form

• Oral
• Parenteral

Market, By Gender

• Male
• Female

Market, By End Use

• Hospitals
• Cancer treatment centers
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE